Chugai Pharmaceutical announced today that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase ...
Oct 5, 2017
0
1
Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live ...
Sep 6, 2017
0
1
Investigators at Children's Hospital Los Angeles have succeeded in better defining a rare pediatric malignant liver disease—a necessary step in achieving an optimum treatment.
Aug 9, 2017
0
0
(HealthDay)—For patients with chronic hepatitis B (CHB), achievement of subcirrhotic range of liver stiffness (sc-LS) with antiviral therapy (AVT) is associated with reduced risk of hepatocellular carcinoma (HCC), according ...
Jul 10, 2017
0
0
Results from the CheckMate 040 study presented today found that nivolumab, an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates, regardless of whether ...
Apr 21, 2017
0
1
According to data from eight studies being presented at The International Liver Congress 2017 in Amsterdam, The Netherlands, there remains continued debate on whether patients are at risk of developing liver cancer after ...
Apr 20, 2017
0
1
(HealthDay)—For patients with end-stage renal disease (ESRD), receipt of hemodialysis (HD) is associated with increased mortality after radiofrequency ablation (RFA) for hepatocellular carcinoma, according to a study published ...
Mar 20, 2017
0
0
Hepatocellular carcinoma is the most common form of liver cancer, but treatment options are limited and many patients are diagnosed in late stages when the disease can't be treated. Now, University of Missouri School of Medicine ...
Feb 28, 2017
0
1
The results of a study by researchers at The University of Nottingham suggest that the risk of liver cancer in patients with cirrhosis may be much lower than previously thought.
Feb 1, 2017
0
0
An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better ...
Jan 18, 2017
0
121
